{"nctId":"NCT00508820","briefTitle":"An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP","startDateStruct":{"date":"2005-02-01","type":"ACTUAL"},"conditions":["Idiopathic Thrombocytopenic Purpura","Thrombocytopenia","Thrombocytopenic Purpura"],"count":407,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: Romiplostim"]}],"interventions":[{"name":"Romiplostim","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is ≥ 18 years of age\n* Subject has a diagnosis of immune (idiopathic) thrombocytopenic purpura per the American Society of Hematology guidelines\n* If Subject is \\> 60 years of age, subject has a written bone marrow aspiration and/or biopsy report consistent with a diagnosis of ITP\n* Subject has received at least 1 prior therapy for ITP\n* Subject's platelet count is ≤ 30,000 or the subject is experiencing bleeding that is uncontrolled with conventional therapies\n* Subject (or legally-acceptable representative) is willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Subject has a history of hematological malignancy, myeloproliferative disorder, myelodysplastic syndrome (MDS), or bone marrow stem cell disorder\n* Subject has participated in any study evaluating PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO), or related platelet product\n* Subject has a known hypersensitivity to any recombinant E coli-derived product\n* Subject has received any therapeutic drug or device that is not approved by the local regulatory health agency for any indication within 4 weeks of Screening\n* Subject is of reproductive potential and is not using adequate contraceptive precautions, in the judgment of the investigator\n* Subject is pregnant or breast feeding\n* Investigator has concerns regarding the subject's ability to comply with the protocol procedures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adverse Events","description":"One or more occurences of one or more adverse events within the participant during the study. Participants with more than one event were only counted once","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162","spread":null},{"groupId":"OG001","value":"215","spread":null}]}]}]},{"type":"SECONDARY","title":"Platelet Response (Definition 1)","description":"Platelet response using definition1 . (a doubling of baseline platelet count and a platelet count of \\>=50 x 10\\^9/L","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"214","spread":null}]}]}]},{"type":"SECONDARY","title":"Platelet Response (Definition 2)","description":"Platelet response using definition 2 (a platelet count increase of \\>=20 x 109/L from baseline)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"220","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":61,"n":168},"commonTop":["Headache","Arthralgia","Fatigue","Nausea","Nasopharyngitis"]}}}